AURA,ZNTL Stock Price and Quote

Elite Trades From Anywhere Elite Trades All Summer

$100 Off Your First Year Get Elite For Just $199.50

Days

Hours

Mins

Sec

Claim Now

Jul 02, 8:33 PMTipRanks spotlight on AURA's 167% analyst upside drives 15% July 2 surge

Peers: IDYA RCUS TNGX CGON NUVL KYMR RYTM BMRN INCY KRYS

| Held by: VTI IWM VXF IBB IWO VHT VTWO ITOT DFAS FESM

Index	RUT
Market Cap	766.47M
Enterprise Value	668.73M
Income	-112.39M
Sales	0.00M
Book/sh	1.67
Cash/sh	1.11
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	113
IPO	Oct 29, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	4.43
P/C	6.68
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.09
Current Ratio	7.09
Debt/Eq	0.16
LT Debt/Eq	0.13
Option/Short	Yes / Yes

EPS (ttm)	-1.76
EPS next Y	-1.67
EPS next Q	-0.38
EPS this Y	9.38%
EPS next Y	-4.55%
EPS next 5Y	4.66%
EPS past 3/5Y	3.57% -11.28%
Sales past 3/5Y	- -
EPS Y/Y TTM	7.21%
Sales Y/Y TTM	-
EPS Q/Q	8.92%
Sales Q/Q	-
Earnings	May 11 AMC
EPS/Sales Surpr.	-25.79% -

Insider Own	38.01%
Insider Trans	-15.24%
Inst Own	34.23%
Inst Trans	-6.26%
ROA	-76.70%
ROE	-95.57%
ROIC	-92.91%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	10.34%
SMA50	2.59%
SMA200	17.90%
Trades

Shs Outstand	103.44M
Shs Float	80.99M
Short Float	6.65%
Short Ratio	8.77
Short Interest	5.39M
52W High	9.53 -22.29%
52W Low	4.73 56.66%
Volatility	8.99% 6.81%
ATR (14)	0.49
RSI (14)	56.91
Beta	0.39
Rel Volume	0.79
Avg Volume	614.24K
Volume	241,268

Perf Week	5.86%
Perf Month	7.70%
Perf Quarter	13.30%
Perf Half Y	35.96%
Perf YTD	35.96%
Perf Year	12.96%
Perf 3Y	-38.30%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	18.80
Prev Close	7.74
Price	7.41
Change	-4.26%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-26-25	Resumed	Evercore ISI	Outperform	$13
May-28-25	Resumed	H.C. Wainwright	Buy	$22
Jul-25-24	Initiated	H.C. Wainwright	Buy	$21
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Apr-17-23	Resumed	BTIG Research	Buy	$38
Jul-19-22	Initiated	JMP Securities	Mkt Outperform	$26

Jun-01-26 08:00AM	Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma (GlobeNewswire)
May-19-26 04:50PM	Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-12-26 04:01PM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-11-26 04:01PM	Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
May-05-26 05:15PM	Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +6.59% -6.85%
09:03AM	Loading…
May-04-26 09:03AM	Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants (GlobeNewswire) +19.12%
06:03AM	Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
06:01AM	Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion (GlobeNewswire)
Apr-07-26 05:15PM	Auranova Announces Closing of Private Placement of Flow-Through Shares (TMX Newsfile)
Apr-01-26 07:30AM	Auranova Resources and Kenorland Minerals Commence Spring Drill Program at South Uchi Project (TMX Newsfile)
Mar-30-26 07:00AM	Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights (GlobeNewswire)
Mar-18-26 10:28AM	Auranova Resources and Kenorland Minerals Announce Upcoming 2026 Spring Drill Program at The South Uchi Project, Ontario (TMX Newsfile)
Mar-05-26 01:33AM	Aura Biosciences Touts Phase 3 bel-sar Momentum, Eyes Mid-Year Bladder Cancer Data at TD Cowen Conference (MarketBeat) -7.32%
Mar-04-26 09:40AM	Is Assertio (ASRT) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-25-26 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.99%
09:40AM	Loading…
Feb-16-26 09:40AM	Are Medical Stocks Lagging Assertio (ASRT) This Year? (Zacks)
Feb-13-26 12:00PM	What Makes Aura Biosciences (AURA) a New Buy Stock (Zacks)
Nov-24-25 04:05PM	Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire) +11.09%
Nov-13-25 07:00AM	Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Sep-03-25 07:00AM	Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-13-25 07:00AM	Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Jul-29-25 04:53PM	4 Artificial Intelligence Stocks (That Aren't Nvidia) You Can Buy and Hold for the Next Decade (Motley Fool)
May-15-25 09:32AM	Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants (GlobeNewswire) +5.71%
06:10AM	Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
06:01AM	Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
May-01-25 04:01PM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-06-25 04:35PM	Is Aura Biosciences (AURA) The Small Cap Stock with Huge Upside Potential? (Insider Monkey)
Apr-02-25 07:00AM	Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors (GlobeNewswire)
Mar-25-25 06:58PM	Aura Biosciences, Inc (AURA) Virtual Urologic Oncology Investor Event Call (Transcript) (SeekingAlpha) -15.40%
Mar-24-25 04:01PM	Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (GlobeNewswire) -6.67%
07:00AM	Loading…
07:00AM	Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress (GlobeNewswire)
Mar-03-25 07:00AM	Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress (GlobeNewswire)
Feb-25-25 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-26-24 08:00AM	Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-12-24 04:05PM	Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Oct-17-24 04:05PM	Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial (GlobeNewswire) +14.09%
Sep-12-24 06:30AM	Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma (GlobeNewswire) +7.94%
Sep-03-24 04:05PM	Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024 (GlobeNewswire) -7.04%
Aug-28-24 04:05PM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-24 04:05PM	Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting (GlobeNewswire)
Aug-08-24 07:00AM	Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jun-06-24 09:55AM	Wall Street Analysts See a 162.63% Upside in Aura Biosciences (AURA): Can the Stock Really Move This High? (Zacks)
May-30-24 04:05PM	Aura Biosciences to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 08:00AM	Aura Biosciences to Host Virtual KOL Event Pioneering a New Standard of Care In Ocular Oncology on May 29, 2024 (GlobeNewswire)
May-10-24 02:58PM	Aura Biosciences Inc (AURA) Reports Q1 2024 Earnings: A Detailed Financial Overview (GuruFocus.com)
May-09-24 01:55PM	AURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-08-24 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-27-24 01:53PM	AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Feb-26-24 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Dec-11-23 09:55AM	Wall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a Bet (Zacks) -8.46%
Dec-07-23 08:00AM	Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma (Business Wire)
Nov-23-23 09:55AM	Wall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to Trade (Zacks)
Nov-09-23 04:05PM	Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) +9.54%
Nov-08-23 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Nov-06-23 10:02PM	Aura Biosciences Announces Pricing of Public Offering of Common Stock (Business Wire) -8.18% -32.55%
04:08PM	Aura Biosciences Announces Proposed Public Offering of Common Stock (Business Wire)
03:00PM	Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma (Business Wire)
Oct-31-23 04:05PM	Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023 (Business Wire) +9.24% +9.93%
Oct-02-23 04:05PM	Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments (Business Wire) -7.47%
Aug-09-23 07:00AM	Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) -6.62%
Jul-31-23 06:07AM	Owning 38% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA), (Simply Wall St.)
May-24-23 04:05PM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire) -5.29%
May-12-23 07:00AM	Aura Biosciences to Participate in the JMP Securities Life Sciences Conference (Business Wire)
May-11-23 04:10PM	Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
May-03-23 07:52AM	Aura Biosciences, Inc. (NASDAQ:AURA) insider upped their holding earlier this year (Simply Wall St.)
Mar-15-23 04:10PM	Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
11:11AM	Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth (Simply Wall St.)
Feb-16-23 10:43AM	Aura Biosciences Releases Data Presentation Of Eye Cancer Candidate (Benzinga) -7.17%
07:00AM	Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration (Business Wire)
Feb-10-23 06:03AM	Why Shares of Aura Biosciences Jumped This Week (Motley Fool)
Feb-09-23 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Dec-24-22 09:27AM	Institutional investors may adopt severe steps after Aura Biosciences, Inc.'s (NASDAQ:AURA) latest 11% drop adds to a year losses (Simply Wall St.)
Dec-16-22 09:54AM	12 Stocks Insiders are Buying Now (Insider Monkey)
Nov-30-22 08:50PM	Aura Biosciences Announces Pricing of Public Offering of Common Stock (Business Wire) -6.02%
04:01PM	Aura Biosciences Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-24-22 06:34AM	Aura Biosciences, Inc. (NASDAQ:AURA) insider upped their holding earlier this year (Simply Wall St.)
Nov-10-22 07:00AM	Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
06:45AM	Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma (Business Wire)
Nov-03-22 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Oct-06-22 10:12AM	Here's Why We're Not Too Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Situation (Simply Wall St.)
Oct-04-22 07:05AM	Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedicals Proprietary Suprachoroidal Space Platform (GlobeNewswire)
Oct-03-22 01:37PM	Aura Biosciences Details Interim Data From Mid-Stage Study Of Ocular Oncology Drug (Benzinga) -19.48%
07:00AM	Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022 (Business Wire)
Sep-28-22 07:00AM	Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer (Business Wire) +19.23%
Sep-27-22 07:00AM	Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022 (Business Wire) +5.12%
Sep-07-22 07:00AM	Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress (Business Wire)
Sep-01-22 07:00AM	Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress (Business Wire)
Aug-11-22 04:15PM	Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) -8.60% +8.89%
Aug-02-22 07:00AM	Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference (Business Wire)
Jul-19-22 03:04PM	JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer" (Benzinga) +7.67%
Jul-17-22 08:36AM	Could The Aura Biosciences, Inc. (NASDAQ:AURA) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Jun-30-22 08:51AM	Aura's stock jumps 11% after announcing Fast Track status for its bladder cancer treatment candidate (MarketWatch) +12.73%
07:00AM	Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer (Business Wire)
Jun-23-22 08:44AM	Aura Biosciences' Belzupacap Sarotalocan At Par With Plaque Radiotherapy In Eye Cancer (Benzinga) -6.00%
Jun-22-22 04:30PM	Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma (Business Wire)
Jun-17-22 07:00AM	Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting (Business Wire) +6.92%
06:40AM	Bullish Aura Biosciences, Inc. (NASDAQ:AURA) investors are yet to receive a pay off on their US$716k bet (Simply Wall St.)

Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.

Chief Financial & Business OfficerMr. Anthony S. Gibney

Chief Medical Officer & President of Research and DevelopmentDr. Jill J. Hopkins M.D.

PresidentMs. Natalie C. Holles

Interim Principal Accounting OfficerMs. Amy Elazzouzi

Ph.D.Dr. Mark Plavsic D.V.M.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gibney Anthony	Officer	Jun 16 '26	Proposed Sale	6.42	12,824	82,330		Jun 16 04:30 PM
Gibney Anthony S	See Remarks	Jun 16 '26	Sale	6.42	12,824	82,330	265,354	Jun 16 04:30 PM
Matrix Capital Management Comp	10% Owner	May 07 '26	Sale	5.64	6,922,870	39,044,987	0	May 11 04:16 PM
Kilroy Conor	Officer	Apr 16 '26	Proposed Sale	7.02	11,738	82,402		Apr 16 06:50 PM
Kilroy Conor	See Remarks	Apr 16 '26	Sale	7.02	11,738	82,401	217,835	Apr 16 06:49 PM
Kilroy Conor	Officer	Feb 17 '26	Proposed Sale	5.05	12,079	61,037		Feb 17 07:51 PM
Plavsic Mark	Officer	Feb 17 '26	Proposed Sale	5.05	15,890	80,271		Feb 17 07:50 PM
Hopkins Janet Jill	Officer	Feb 17 '26	Proposed Sale	5.06	20,401	103,231		Feb 17 07:50 PM
Elazzouzi Amy	Officer	Feb 17 '26	Proposed Sale	5.06	8,549	43,261		Feb 17 07:50 PM
de los Pinos Elisabet	Officer	Feb 17 '26	Proposed Sale	5.06	47,648	241,063		Feb 17 07:49 PM
Kilroy Conor	See Remarks	Feb 17 '26	Sale	5.05	12,079	60,999	167,234	Feb 17 07:48 PM
Plavsic Mark	Chief Technology Officer	Feb 17 '26	Sale	5.05	15,890	80,244	181,397	Feb 17 07:47 PM
Hopkins Janet Jill	Chief Medical Officer	Feb 17 '26	Sale	5.06	20,401	103,229	232,284	Feb 17 07:47 PM
Elazzouzi Amy	Senior Vice President, Finance	Feb 17 '26	Sale	5.06	8,549	43,258	75,532	Feb 17 07:47 PM
de los Pinos Elisabet	See Remarks	Feb 17 '26	Sale	5.06	47,648	241,099	409,815	Feb 17 07:46 PM
Elazzouzi Amy	Officer	Jan 20 '26	Proposed Sale	4.86	1,581	7,684		Jan 20 06:42 PM
de los Pinos Elisabet	Officer	Jan 20 '26	Proposed Sale	4.86	16,928	82,234		Jan 20 06:42 PM
Elazzouzi Amy	Senior Vice President, Finance	Jan 20 '26	Sale	4.86	1,581	7,684	84,081	Jan 20 06:41 PM
de los Pinos Elisabet	See Remarks	Jan 20 '26	Sale	4.86	16,928	82,270	457,463	Jan 20 06:41 PM
Hopkins Janet Jill	Officer	Nov 17 '25	Proposed Sale	5.42	17,109	92,735		Nov 17 05:57 PM
Hopkins Janet Jill	Chief Medical Officer	Nov 17 '25	Sale	5.42	17,109	92,731	252,685	Nov 17 05:56 PM
Elazzouzi Amy	Officer	Oct 29 '25	Proposed Sale	6.35	896	5,690		Oct 29 05:07 PM
de los Pinos Elisabet	Officer	Oct 29 '25	Proposed Sale	6.35	9,049	57,461		Oct 29 05:06 PM
Elazzouzi Amy	Senior Vice President, Finance	Oct 29 '25	Sale	6.35	896	5,690	85,662	Oct 29 05:05 PM
de los Pinos Elisabet	See Remarks	Oct 29 '25	Sale	6.35	9,049	57,461	474,391	Oct 29 05:05 PM
Plavsic Mark	Officer	Oct 16 '25	Proposed Sale	6.35	12,169	77,273		Oct 16 05:45 PM
Plavsic Mark	Chief Technology Officer	Oct 16 '25	Sale	6.35	12,169	77,273	197,287	Oct 16 05:44 PM
Elazzouzi Amy	Senior Vice President, Finance	Aug 18 '25	Option Exercise	3.96	12,899	51,103	94,280	Aug 18 04:34 PM
Elazzouzi Amy	Senior Vice President, Finance	Aug 18 '25	Sale	6.70	7,722	51,737	86,558	Aug 18 04:34 PM
AMY F ELAZZOUZI	Officer	Aug 18 '25	Proposed Sale	6.70	7,722	51,751		Aug 18 04:20 PM

ZNTL Zentalis Pharmaceuticals Inc daily Stock Chart

Peers: CCCC CHRS REPL ALEC CLLS IMRX ELDN LENZ GLSI RZLT

| Held by: VTI IWM VXF IWN FESM IWC DFAS VHT PRFZ AVSC

Index	RUT
Market Cap	334.93M
Enterprise Value	161.82M
Income	-124.13M
Sales	0.00M
Book/sh	2.57
Cash/sh	2.97
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	106
IPO	Apr 03, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.83
P/C	1.58
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	6.19
Current Ratio	6.19
Debt/Eq	0.21
LT Debt/Eq	0.19
Option/Short	Yes / Yes

EPS (ttm)	-1.74
EPS next Y	-1.68
EPS next Q	-0.48
EPS this Y	-1.45%
EPS next Y	13.53%
EPS next 5Y	7.13%
EPS past 3/5Y	24.78% 7.86%
Sales past 3/5Y	- -
EPS Y/Y TTM	44.78%
Sales Y/Y TTM	-100.00%
EPS Q/Q	25.31%
Sales Q/Q	-
Earnings	May 12 AMC
EPS/Sales Surpr.	-4.89% -

Insider Own	36.08%
Insider Trans	33.22%
Inst Own	52.63%
Inst Trans	-1.45%
ROA	-38.97%
ROE	-51.93%
ROIC	-57.12%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	19.96%
SMA50	18.19%
SMA200	78.66%
Trades

Shs Outstand	71.16M
Shs Float	45.50M
Short Float	10.95%
Short Ratio	2.21
Short Interest	4.98M
52W High	6.95 -32.30%
52W Low	1.15 309.13%
Volatility	13.96% 9.15%
ATR (14)	0.37
RSI (14)	62.96
Beta	1.94
Rel Volume	0.36
Avg Volume	2.25M
Volume	398,009

Perf Week	16.46%
Perf Month	26.48%
Perf Quarter	78.90%
Perf Half Y	248.52%
Perf YTD	248.52%
Perf Year	273.41%
Perf 3Y	-83.11%
Perf 5Y	-89.95%
Perf 10Y	-
Recom	2.11
Target Price	6.50
Prev Close	4.46
Price	4.70
Change	5.49%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-17-26	Resumed	Wells Fargo	Equal Weight	$5
Aug-12-24	Upgrade	Wedbush	Underperform → Neutral	$4
Jun-20-24	Downgrade	UBS	Buy → Neutral	$28 → $5
Jun-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-18-24	Downgrade	Wedbush	Neutral → Underperform	$15 → $4
Jun-18-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$38 → $8
Jun-18-24	Downgrade	Jefferies	Buy → Hold	$42 → $6
Nov-08-23	Downgrade	Wedbush	Outperform → Neutral	$38 → $12
Nov-07-23	Downgrade	Leerink Partners	Outperform → Market Perform	$15
Jul-12-22	Initiated	Cowen	Outperform
Apr-06-22	Initiated	Wells Fargo	Overweight	$67
Oct-07-21	Resumed	Jefferies	Buy	$120
Sep-30-21	Initiated	Stifel	Buy	$84
Sep-29-21	Initiated	Oppenheimer	Outperform	$90
May-21-21	Initiated	UBS	Buy	$91
Jan-20-21	Initiated	Wedbush	Outperform	$65
Sep-29-20	Initiated	Cantor Fitzgerald	Overweight	$44
Aug-27-20	Initiated	H.C. Wainwright	Buy	$43
Apr-28-20	Initiated	SVB Leerink	Outperform	$45
Apr-28-20	Initiated	Morgan Stanley	Overweight	$45

Show Previous Ratings

Jun-01-26 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-27-26 04:05PM	Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy (GlobeNewswire)
May-21-26 05:39PM	Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 (GlobeNewswire) +11.59%
May-13-26 04:05PM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-12-26 04:05PM	Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress (GlobeNewswire)
08:00AM	Loading…
May-05-26 08:00AM	Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer (GlobeNewswire)
May-01-26 05:30PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-21-26 10:27AM	Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer (GlobeNewswire)
Apr-17-26 03:15PM	Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 (GlobeNewswire) -7.57%
Apr-10-26 10:30AM	BC-Most Active Stocks (Associated Press) +49.55%
Apr-09-26 08:00AM	Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer (GlobeNewswire) +60.14%
Apr-01-26 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.83%
Mar-26-26 04:05PM	Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates (GlobeNewswire) -21.35%
Mar-17-26 04:30PM	Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 (GlobeNewswire) -7.88%
Feb-18-26 08:00AM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
05:09AM	Loading…
Feb-16-26 05:09AM	Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon (MarketBeat)
Feb-03-26 04:05PM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference (GlobeNewswire) +12.35% -9.57%
Jan-13-26 08:45AM	Mitsui Sumitomo Continues to Build WR Berkley Stake (24/7 Wall St.)
Jan-12-26 10:35AM	Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 (PR Newswire) -6.68%
Jan-06-26 08:00AM	Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 (GlobeNewswire) +29.93%
Nov-10-25 04:05PM	Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress (GlobeNewswire) +6.06%
Nov-03-25 05:25PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.33%
08:15AM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-13-25 04:05PM	Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-01-25 05:20PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.79%
Sep-02-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-28-25 04:15PM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-25 04:05PM	Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Aug-06-25 04:05PM	Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress (GlobeNewswire) +5.07%
Jul-01-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
05:00PM	Loading…
Jun-02-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.79% +6.25%
May-14-25 04:05PM	Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress (GlobeNewswire) +5.88%
May-01-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-28-25 08:00AM	Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC (GlobeNewswire)
Apr-23-25 04:05PM	Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting (GlobeNewswire)
Apr-01-25 05:30PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -12.58%
Mar-26-25 04:05PM	Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates (GlobeNewswire) -5.88%
Mar-25-25 04:40PM	Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire) -5.56%
Mar-15-25 11:25AM	Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer (GlobeNewswire)
Mar-03-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.25%
08:00AM	Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer (GlobeNewswire)
Feb-24-25 04:05PM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-21-25 12:21AM	Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently (Insider Monkey) -6.07%
Feb-03-25 05:42PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:35AM	Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-30-25 10:20AM	Zentalis price target lowered to $10 from $20 at Oppenheimer (TipRanks) -12.17%
Jan-29-25 07:00AM	Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer (GlobeNewswire) -21.25%
Jan-28-25 04:05PM	Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development (GlobeNewswire)
Jan-09-25 12:00PM	Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
07:00AM	Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies (GlobeNewswire)
Jan-02-25 04:53PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.00%
Dec-12-24 07:00AM	Zentalis Pharmaceuticals Announces Key Management Appointments (GlobeNewswire) -10.57%
Dec-02-24 04:35PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.20%
Nov-13-24 08:00AM	Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib (GlobeNewswire) +5.66%
Nov-01-24 07:04PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +21.61% +12.35%
Oct-18-24 03:05PM	State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings (GuruFocus.com)
Oct-07-24 03:03PM	FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc (GuruFocus.com) -7.72%
Sep-17-24 12:15PM	FDA lifts partial clinical hold on Zentalis Pharmas cancer WEE1 inhibitor (Pharmaceutical Technology) +11.41%
Sep-16-24 09:00AM	FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers (Benzinga) +13.58%
07:00AM	Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies (GlobeNewswire)
Sep-09-24 07:00AM	Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024 (GlobeNewswire)
Sep-03-24 04:40PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.92%
Aug-26-24 11:58AM	Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why (Zacks)
Aug-09-24 02:53PM	ZNTL Stock Earnings: Zentalis Pharma Misses EPS for Q2 2024 (InvestorPlace) -9.37%
07:00AM	Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress (GlobeNewswire)
Aug-01-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.00%
Jul-01-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -14.80%
Jun-19-24 10:23AM	Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold (Zacks)
04:52AM	FDA places partial clinical hold on Zentalis trials of azenosertib for cancer (Clinical Trials Arena)
Jun-18-24 07:00AM	Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program (GlobeNewswire) -50.66%
Jun-03-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-01-24 02:43AM	Insider Selling at Zentalis Pharmaceuticals Inc (ZNTL): President, Interim CFO Cam Gallagher ... (GuruFocus.com)
May-30-24 07:00AM	Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-29-24 07:00AM	Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors (GlobeNewswire)
May-23-24 05:01PM	Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -5.84%
May-14-24 07:00AM	Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire)
May-08-24 10:27AM	Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating (MT Newswires)
May-07-24 09:04PM	Zentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic ... (GuruFocus.com) +5.03%
01:54PM	ZNTL Stock Earnings: Zentalis Pharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress (GlobeNewswire)
May-01-24 05:30PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-24 04:05PM	Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024 (GlobeNewswire) -10.54% +8.25%
Apr-01-24 05:30PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-24 09:55AM	Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet (Zacks) +5.30%
07:00AM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-27-24 07:01PM	Zentalis Pharmaceuticals Inc (ZNTL) Reports Full Year 2023 Financial Results and Provides ... (GuruFocus.com)
07:00AM	Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates (GlobeNewswire)
Feb-14-24 09:35AM	Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL) (Zacks) +10.34%
Feb-13-24 07:00AM	Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference (GlobeNewswire) -5.83%
Feb-08-24 12:00PM	What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock (Zacks)
Feb-05-24 11:26PM	Insider Sell: President Cam Gallagher Sells 11,552 Shares of Zentalis Pharmaceuticals Inc (ZNTL) (GuruFocus.com)
Feb-01-24 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-25-24 07:00AM	Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments (GlobeNewswire)
Jan-08-24 07:00AM	Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform (Business Wire) +7.15%
Jan-02-24 04:49PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.54%
Dec-01-23 05:39PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-13-23 09:03PM	Director David Johnson's Strategic Purchase of Zentalis Pharmaceuticals Inc Shares (GuruFocus.com) +14.42%
Nov-09-23 07:00AM	Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen (GlobeNewswire)
Nov-06-23 07:13PM	Zentalis Pharmaceuticals Inc (ZNTL) Reports Q3 2023 Financial Results and Operational Updates (GuruFocus.com) -30.20% -18.27%

Zentalis Pharmaceuticals, Inc. is a clinical oncology innovator developing an oral, non-chemotherapy, biomarker-driven treatment approach for ovarian cancer and multiple tumor types. The therapeutics development and biomarker expertise is advancing monotherapy and combination studies of its investigational potential first-in-class WEE1 inhibitor, azenosertib. It is focused on translating WEE1 science into clinical practice, aiming to equip physicians with a targeted, orally available medicine that enhances treatment experience, choice, and outcomes. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

CEOMs. Julie M. Eastland M.B.A.

Chief Legal Officer & Corporate SecretaryMr. James B. Bucher J.D.

Ph.D.Dr. Ingmar Bruns M.D.

SVP of Finance & Principal Accounting OfficerMr. Vincent A. Vultaggio

Chief Technical OfficerMr. Robert J. DiVasto P.E.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bruns Ingmar	Chief Medical Officer	Feb 06 '26	Sale	2.43	2,962	7,197	33,667	Feb 10 09:10 PM
Bruns Ingmar	Chief Medical Officer	Feb 09 '26	Sale	2.39	335	802	33,332	Feb 10 09:10 PM
Vultaggio Vincent	PAO and PFO	Feb 06 '26	Sale	2.43	29,951	72,772	156,779	Feb 10 09:10 PM
Vultaggio Vincent	PAO and PFO	Feb 10 '26	Sale	2.42	6,894	16,699	146,506	Feb 10 09:10 PM
Vultaggio Vincent	PAO and PFO	Feb 09 '26	Sale	2.39	3,379	8,086	153,400	Feb 10 09:10 PM
EASTLAND JULIA MARIE	CEO & President	Feb 06 '26	Sale	2.43	7,866	19,112	80,022	Feb 10 09:09 PM
EASTLAND JULIA MARIE	CEO & President	Feb 09 '26	Sale	2.39	889	2,127	79,133	Feb 10 09:09 PM
Vultaggio Vincent	PAO and PFO	Feb 02 '26	Sale	2.55	2,540	6,477	187,286	Feb 04 08:27 PM
Vultaggio Vincent	PAO and PFO	Feb 03 '26	Sale	2.52	556	1,398	186,730	Feb 04 08:27 PM
WALTERS GROUP	10% Owner	Dec 31 '25	Buy	1.20	6,459,973	7,751,968	13,509,973	Jan 08 04:57 PM
Matrix Capital Management Comp	10% Owner	Dec 15 '25	Sale	1.33	7,500,000	9,975,000	6,459,973	Dec 15 05:24 PM

$100 Off Your First Year Get Elite For Just $199.50

AURA

Aura Biosciences Inc

ZNTL

Zentalis Pharmaceuticals Inc

Upgrade your Finviz experience